Private company

9 METERS BIOPHARMA, INC.

9 METERS BIOPHARMA, INC. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Raleigh, North Carolina.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersRaleigh, North Carolina1
  • Incorporated inDE2
  • Business address4509 Creedmoor Road, Suite 600, Raleigh, Nc 276122
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2017

-3.4%Gross margin3
593.2%Operating margin4
-616.3%Net margin4
-53.7%Revenue growth, 20173
-$5.1MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2017

  • Cost of revenue30¢$1.9M
  • Research and development63¢$4.0M
  • Interest7¢$436.3K

Out of $1.9M in revenue.34 The company lost money this year.

Financial statements

Revenue3$1.9M in 2017−54% since 2016
0$2.0M$4.0M$6.0M2016: $4.1M$4.1M20162017: $1.9M$1.9M2017−54%
Gross profit3-$64.0K in 2017
-$200.0K0$200.0K$400.0K$600.0K$800.0K2016: $736.0K$736.0K20162017: -$64.0K-$64.0K2017
Operating income34$11.2M in 2017
-$10.0M-$5.0M0$5.0M$10.0M$15.0M2016: -$5.9M-$5.9M20162017: $11.2M$11.2M2017
Net income34-$11.6M in 2017+87% since 2016
-$15.0M-$10.0M-$5.0M02016: -$6.2M-$6.2M20162017: -$11.6M-$11.6M2017+87%
Fiscal year20162017
Revenue$4.1M3$1.9M3
Cost of revenue$3.3M3$1.9M3
Gross profit$736.0K3-$64.0K3
Research and development$270.0K3$4.0M4
Operating expenses
Operating income-$5.9M3$11.2M4
Interest$825.0K3$436.3K4
Income before tax
Income tax$2.0K3$04
Net income-$6.2M3-$11.6M4
Earnings per share
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Compare 9 METERS BIOPHARMA, INC. with another company

Corporate structure

9 METERS BIOPHARMA, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of 9 METERS BIOPHARMA, INC.

  • ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SC 13G/A on 9 METERS BIOPHARMA, INC., latest Feb 7, 2024 (3 filings since Feb 10, 2022)
  • OrbiMed Israel BioFund GP Limited Partnership Filed SC 13D/A on 9 METERS BIOPHARMA, INC., latest Jul 1, 2022
  • 9 METERS BIOPHARMA, INC. Raleigh, North Carolina

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What 9 METERS BIOPHARMA, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$88.0K9 Dec 31, 2022$85.1K9 Dec 31, 2021+3.3%
Accumulated depreciation$77.6K9 Dec 31, 2022$69.0K9 Dec 31, 2021+12.3%
Property and equipment, net$10.4K9 Dec 31, 2022$16.1K9 Dec 31, 2021−35.3%
Operating-lease assets (leased space)$112.3K9 Dec 31, 2022$166.6K9 Dec 31, 2021−32.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$12.6M9 Dec 31, 2022$47.0M9 Dec 31, 2021−73.1%

Leadership

Who has led 9 METERS BIOPHARMA, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Christopher P. Prior2018
  2. Sandeep Laumas2019
  3. John Temperato2020–2023

Chair

  1. Jawahar Tandon2016
  2. Sandeep Laumas2018–2019

President

  1. Jay P. Madan2018–2020

Chief financial officer

  1. David Lewis Olert2016–2018
  2. Edward J. Sitar2019–2021
  3. Bethany Sensenig2022–2023

Chief operating officer

  1. June Sherie Almenoff2018
20202025
Board members and other officers (22)

Former names

  • INNOVATE BIOPHARMACEUTICALS, INC.Sep 8, 2017 to May 5, 20202
  • Monster Digital, Inc.Sep 9, 2015 to Jan 11, 20182
  • Tandon Digital, Inc.Jun 19, 2012 to Aug 12, 20152

Timeline

  1. Jul 18, 20238-K Entered a material agreement; Bankruptcy or receivership; Debt or obligation accelerated39
  2. Jun 16, 20238-K Listing notice or transfer40
  3. May 30, 20238-K Executive or director change41
  4. May 22, 20238-K Other events42
  5. May 19, 20238-K Entered a material agreement; Debt or obligation accelerated43
  6. May 15, 20238-K Results of operations44
  7. Apr 27, 20238-K Entered a material agreement; Debt or obligation accelerated45
  8. Apr 6, 20238-K Entered a material agreement; Listing notice or transfer46
  9. Apr 5, 20238-K Other events47
  10. Mar 28, 20238-K Results of operations48
  11. Mar 15, 20238-K Entered a material agreement; Other events49
  12. Mar 13, 20238-K Other events50
  13. May 4, 2020New chief executive John Temperato becomes CEO10
  14. May 23, 2019New chief executive Sandeep Laumas becomes CEO11
  15. Feb 8, 2018New chief executive Christopher P. Prior becomes CEO12

Calendar

When it reported results

  1. May 15, 2023Reported quarterly or annual results44
  2. Mar 28, 2023Reported quarterly or annual results48
  3. Nov 8, 2022Reported quarterly or annual results51
  4. Aug 15, 2022Reported quarterly or annual results52
  5. May 16, 2022Reported quarterly or annual results53
  6. Mar 23, 2022Reported quarterly or annual results54
  7. Nov 15, 2021Reported quarterly or annual results55

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

100 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 40 major events, 30 insider forms, 4 large holders, 18 other. The latest 20:

  1. Feb 7, 2024SC 13G/A EDGAR
  2. Jul 21, 2023144 EDGAR
  3. Jul 19, 2023144 EDGAR
  4. Jul 18, 20238-K EDGAR
  5. Jun 16, 20238-K EDGAR
  6. May 30, 20238-K EDGAR
  7. May 22, 20238-K EDGAR
  8. May 19, 2023PRE 14A EDGAR
  9. May 19, 20238-K EDGAR
  10. May 15, 202310-Q EDGAR
  11. May 15, 20238-K EDGAR
  12. Apr 28, 202310-K/A EDGAR
  13. Apr 27, 20238-K EDGAR
  14. Apr 21, 2023144 EDGAR
  15. Apr 21, 20234 EDGAR
  16. Apr 6, 20238-K EDGAR
  17. Apr 5, 20238-K EDGAR
  18. Mar 31, 20234 PRIMARY DOCUMENT EDGAR
  19. Mar 31, 20234 PRIMARY DOCUMENT EDGAR
  20. Mar 31, 20234 PRIMARY DOCUMENT EDGAR

The 100 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

11 open-market trades by officers, directors and large owners since October 2021: 10 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 21, 2023Sensenig BethanyChief Financial OfficerSale9,100$1.21$11.0KForm 4
Jul 6, 2022Temperato JohnChief Executive OfficerBuy125,000$0.23$28.8KForm 4
Jul 1, 2022Sirgo Mark ADirectorBuy175,000$0.25$43.8KForm 4
May 23, 2022Constantino Michael T.DirectorBuy16,000$0.48$7.7KForm 4
May 18, 2022Temperato JohnChief Executive OfficerBuy50,000$0.45$22.5KForm 4
May 18, 2022Sirgo Mark ADirectorBuy106,383$0.47$50.0KForm 4
Mar 3, 2022Sirgo Mark ADirectorBuy86,450$0.58$50.1KForm 4
Mar 3, 2022Temperato JohnChief Executive OfficerBuy100,000$0.56$56.0KForm 4
Dec 2, 2021Sirgo Mark ADirectorBuy50,000$0.89$44.5KForm 4
Nov 18, 2021Sirgo Mark ADirectorBuy20,000$1.06$21.2KForm 4
Nov 18, 2021Temperato JohnChief Executive OfficerBuy50,000$1.05$52.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How 9 METERS BIOPHARMA, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAR9 METERS BIOPHARMA, INC.1
  • CIK0001551986
  • Employer ID (EIN)27-39484651
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4509 Creedmoor Road, Suite 600, Raleigh, NC 276121
  • Phone919-275-19331
  • Shares outstanding14,459,690 as of May 12, 20237
  • Public float$67.2M as of Jun 30, 202258
  • On EDGAR sinceJun 19, 20121
  • Filings591 in all: 8-K (176), 4 (143), CORRESP (33), 3 (31), UPLOAD (24), 10-Q (21), SC TO-I/A (14), D (12)1
    All 46 form types

    424B5 (10), DEFA14A (10), PRE 14A (8), S-1/A (8), S-8 (8), 10-K (7), DEF 14A (7), EFFECT (7), S-3/A (6), SC 13D/A (6), 424B3 (5), S-3 (5), 4/A (4), SC 13G (4), SC 13G/A (4), 144 (3), 8-K/A (3), CT ORDER (3), NT 10-Q (3), SC TO-I (3), 10-K/A (2), 25-NSE (2), PRER14A (2), S-1 (2), SC 13D (2), 25 (1), 424B4 (1), 8-A12B (1), CERTNAS (1), D/A (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), FWP (1), POS AM (1), PREM14A (1), RW (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2023
    Quarterly report (10-Q) May 15, 2023
    Proxy statement (DEF 14A) Aug 2, 2022
    Latest 8-K (8-K) Jul 18, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
    SEC EDGAROther events
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
    SEC EDGAROther events
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58